Combining Brain-Penetrant CHK1 & PRMT5 Inhibitors to Enhance Efficacy & Optimize Pharmacodynamics in Preclinical Models

• See the rationale behind PharmaEngine’s combination of CHK1 and PRMT5 inhibitors with preclinical examples

• Understanding alternation of pharmacodynamic markers of CHK1 and PRMT5 post corresponding inhibitor treatments

• Discovering combinations of CHK1 or PRMT5 inhibitors to standard of cares (SoCs) in corresponding indications

Speakers:

Jack Cheng

Associate Director

PharmaEngine, Inc